Genomic Health (NASDAQ: GHDX) reported Q3 EPS of ($0.36), $0.18 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $73.6 million versus the consensus estimate of $73.12 million.

More than 27,820 Oncotype DX® test results were delivered in the third quarter of 2015, compared with more than 23,700 test results delivered in the same period in 2014, an increase of 17 percent. International test results delivered grew 30 percent compared with the prior year and represented approximately 22 percent of total test volume in the third quarter of 2015.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.